High-dose chemotherapy and PBPC autografting in indolent lymphomas: Evaluation of minimal residual disease and molecular follow-up.

被引：0
|
作者：
Corradini, P
Astolfi, M
Caracciolo, D
Bondesan, P
Voena, C
Vitolo, U
Cinque, F
Pileri, A
Tarella, C
机构：
[1] Az Osped S Giovanni Battista, Div Osped Ematol, Torino, Italy
[2] Univ Turin, Az Osped S Giovanni Battista, Div Ematol, Torino, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
634
引用
收藏
页码：S183 / S183
页数：1
相关论文
共 50 条
  • [1] High-dose (HDS) chemotherapy and PBPC autografting in low- and intermediate-grade B-cell lymphomas: Analysis of minimal residual disease and molecular follow-up.
    Corradini, P
    Astolfi, M
    Caracciolo, D
    Bondesan, P
    Cherasco, C
    Pileri, A
    Tarella, C
    BLOOD, 1995, 86 (10) : 3229 - 3229
  • [2] High-dose (HDS) chemotherapy and PBPO autografting in follicular and mantle cell lymphomas: Analysis of minimal residual disease and molecular follow-up
    Corradini, P
    Astolfi, M
    Caracciolo, D
    Bondesan, P
    Cherasco, C
    Pileri, A
    Tarella, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1383 - 1383
  • [3] Long-term molecular follow-up in indolent lymphomas following high-dose chemotherapy and PBPC autografting: durable molecular and clinical remissions can be achieved in follicular subtypes
    Corradini, P
    Ladetto, M
    Astolfi, A
    Voena, C
    Villa, C
    Vitolo, U
    Benedetti, F
    Pileri, A
    Tarella, C
    LEUKEMIA, 2001, 15 (12) : 2014 - 2014
  • [4] High-dose chemotherapy and PBPC autografting induce durable molecular remissions in follicular lymphomas, but not in small lymphocytic and mantle cell lymphomas.
    Corradini, P
    Astolfi, M
    Voena, C
    Caracciolo, D
    Vitolo, U
    Benedetti, F
    Pileri, A
    Tarella, C
    BLOOD, 1998, 92 (10) : 463A - 463A
  • [5] Long-term molecular follow-up in indolent lymphomas treated with high-dose chemotherapy and autografting: durable clinical and molecular remissions can be attained in follicular subtype
    Corradini, P
    Ladetto, M
    Astolfi, M
    Rizzo, E
    Benedetti, F
    Vitolo, U
    Caracciolo, D
    Zallio, F
    Boccadoro, M
    Pileri, A
    Tarella, C
    BONE MARROW TRANSPLANTATION, 2003, 31 : S122 - S122
  • [6] Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
    Corradini, P
    Astolfi, M
    Cherasco, C
    Ladetto, M
    Voena, C
    Caracciolo, D
    Pileri, A
    Tarella, C
    BLOOD, 1997, 89 (02) : 724 - 731
  • [7] Long-term molecular follow-up in indolent lymphomas treated with HDS and PBPC autografting: durable molecular and clinical remissions can be achieved in follicular subtypes
    Corradini, P
    Ladetto, M
    Astolfi, M
    Caracciolo, D
    Voena, C
    Villa, C
    Rizzo, E
    Vitolo, U
    Benedetti, F
    Pileri, A
    Tarella, C
    BONE MARROW TRANSPLANTATION, 2001, 27 : S234 - S234
  • [8] Immunocytochemical (ICC) detection of minimal residual disease in bone marrow and PBPC in breast cancer patients undergoing high-dose chemotherapy.
    Flamini, E
    Cotignoli, T
    Frassineti, GL
    Rosti, G
    De Paola, F
    Mancini, D
    BONE MARROW TRANSPLANTATION, 1998, 21 : S56 - S56
  • [9] Long-term molecular follow-up in indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Durable molecular and clinical remiussion can be achieved only in follicular subtypes.
    Corradini, P
    Ladetto, M
    Astolfi, M
    Voena, C
    Rizzo, E
    Sametti, S
    Benedetti, F
    Vitolo, U
    Caracciolo, D
    Pileri, A
    Tarella, C
    BLOOD, 2001, 98 (11) : 681A - 681A
  • [10] High-dose (HDS) chemotherapy in multiple myeloma: Residual tumor cells are detectable in PBPC and BM cell harvests and after single or double autografting.
    Corradini, P
    Astolfi, M
    Ladetto, M
    Campana, S
    Comoglio, F
    Tarella, C
    Boccadoro, M
    Pileri, A
    BLOOD, 1995, 86 (10) : 810 - 810
12345